These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 21198705)

  • 21. Oesophageal and gastric pH profiles in patients with gastro-oesophageal reflux disease and Barrett's oesophagus treated with proton pump inhibitors.
    Gerson LB; Boparai V; Ullah N; Triadafilopoulos G
    Aliment Pharmacol Ther; 2004 Sep; 20(6):637-43. PubMed ID: 15352912
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An analysis of persistent symptoms in acid-suppressed patients undergoing impedance-pH monitoring.
    Sharma N; Agrawal A; Freeman J; Vela MF; Castell D
    Clin Gastroenterol Hepatol; 2008 May; 6(5):521-4. PubMed ID: 18356117
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characteristics of symptomatic reflux episodes on Acid suppressive therapy.
    Tutuian R; Vela MF; Hill EG; Mainie I; Agrawal A; Castell DO
    Am J Gastroenterol; 2008 May; 103(5):1090-6. PubMed ID: 18445095
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Control of esophageal and intragastric pH with compounded and manufactured omeprazole in patients with reflux esophagitis: a pilot study.
    Moretzsohn LD; Carvalho EB; Franco JD; Soares MP; Brito EM; Belarmino K; Coelho LG
    Can J Clin Pharmacol; 2009; 16(1):e264-72. PubMed ID: 19383986
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical trial: persistent gastro-oesophageal reflux symptoms despite standard therapy with proton pump inhibitors - a follow-up study of intraluminal-impedance guided therapy.
    Becker V; Bajbouj M; Waller K; Schmid RM; Meining A
    Aliment Pharmacol Ther; 2007 Nov; 26(10):1355-60. PubMed ID: 17900268
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Correlation between gastric pH and gastro-oesophageal reflux contents: ambulatory pH-impedance monitoring results.
    Roman S; Serraj I; Damon H; Mion F
    Neurogastroenterol Motil; 2007 Jul; 19(7):562-8. PubMed ID: 17593137
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [How to raise efficacy of gastroesophageal reflux disease treatment].
    Vakhrushev IaM; Potapova LO; Muravtseva OV
    Ter Arkh; 2009; 81(2):27-30. PubMed ID: 19334485
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Diagnosis and therapy of gastroesophageal reflux disease with lansoprazole].
    Bordin DS; Masharova AA
    Eksp Klin Gastroenterol; 2008; (5):85-90. PubMed ID: 19145922
    [No Abstract]   [Full Text] [Related]  

  • 29. Laryngopharyngeal reflux disease with nocturnal gastric acid breakthrough while on proton pump inhibitor therapy.
    Sato K
    Eur Arch Otorhinolaryngol; 2006 Dec; 263(12):1121-6. PubMed ID: 16845517
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of the acidity index and integrated intragastric acidity in 645 patients presenting with gastroesophageal reflux disease symptoms.
    Blonski WC; Shih GL; Brensinger CM; Katzka DA; Metz DC
    Scand J Gastroenterol; 2006 Apr; 41(4):382-9. PubMed ID: 16635904
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impedance-pH monitoring in proton pump inhibitor resistant patients: ready for clinical application?
    Galmiche JP
    Gut; 2006 Oct; 55(10):1379-81. PubMed ID: 16966695
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increased frequency and enhanced perception of reflux in non-erosive reflux disease patients non-responders to proton pump inhibitors.
    Ribolsi M; Emerenziani S; Petitti T; Addarii MC; Balestrieri P; Cicala M
    Dig Liver Dis; 2012 Jul; 44(7):549-54. PubMed ID: 22366345
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Night acid "bursting": treatment of patients with gastroesophageal reflux disease].
    Vasil'ev IuV; Beliaeva VS
    Eksp Klin Gastroenterol; 2007; (3):83-91. PubMed ID: 17937011
    [No Abstract]   [Full Text] [Related]  

  • 34. Long-term outcome of Nissen fundoplication in non-erosive and erosive gastro-oesophageal reflux disease.
    Broeders JA; Draaisma WA; Bredenoord AJ; Smout AJ; Broeders IA; Gooszen HG
    Br J Surg; 2010 Jun; 97(6):845-52. PubMed ID: 20473997
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gastroesophageal reflux disease poorly responsive to single-dose proton pump inhibitors in patients without Barrett's esophagus: acid reflux, bile reflux, or both?
    Tack J; Koek G; Demedts I; Sifrim D; Janssens J
    Am J Gastroenterol; 2004 Jun; 99(6):981-8. PubMed ID: 15180713
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Omeprazole-Mg 20.6 mg is superior to lansoprazole 15 mg for control of gastric acid: a comparison of over-the-counter doses of proton pump inhibitors.
    Miner PB; McKean LA; Gibb RD; Erasala GN; Ramsey DL; McRorie JW
    Aliment Pharmacol Ther; 2010 Apr; 31(8):846-51. PubMed ID: 20146702
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pathogenesis of Potassium-Competitive Acid Blocker-Resistant Non-Erosive Reflux Disease.
    Kawami N; Hoshino S; Hoshikawa Y; Takenouchi N; Umezawa M; Hanada Y; Kaise M; Iwakiri K
    Digestion; 2018; 98(3):194-200. PubMed ID: 29870976
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stability of gastric secretory inhibition during 6-month treatment with omeprazole in patients with gastroesophageal reflux disease.
    Tefera S; Hatlebakk JG; Berstad A
    Am J Gastroenterol; 2001 Apr; 96(4):969-74. PubMed ID: 11316213
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improved diagnosis of gastro-oesophageal reflux in patients with unexplained chronic cough.
    Blondeau K; Dupont LJ; Mertens V; Tack J; Sifrim D
    Aliment Pharmacol Ther; 2007 Mar; 25(6):723-32. PubMed ID: 17311606
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [pH-impedancemetry: clinical implications].
    Bertolini D; Roman S; Dumonceau JM
    Rev Med Suisse; 2008 Sep; 4(169):1873-4, 1876-8. PubMed ID: 18831408
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.